comprehensive -WSS

comprehensive

author：focus 2025-10-01 22:59:30 - browse：437

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： The unintended consequences of overturning Roe v. Wade

WSS

Medical leaders decry Supreme Court decision on affirmative action

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why the quest to eradicate polio has stumbled

People with substance use disorder deserve online privacy

Medical leaders decry Supreme Court decision on affirmative action

Covid’s new normal has set in amid another rise in cases

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Apple is now the first public company to be valued at $3 trillion

The unintended consequences of overturning Roe v. Wade

Medicare details structure of new drug price negotiation program

Patients, doctors press FTC to beef up hospital merger scrutiny

Activists slam private health insurers over coverage restrictions

The unintended consequences of overturning Roe v. Wade

Anesthesiologist group: stop taking Ozempic before surgery

Free Covid tests will again be offered to all U.S. households

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why the drug industry's warnings on the IRA's impact fall short

hotspot

Why the drug industry's warnings on the IRA's impact fall short

Midwives could help bridge maternal health disparities in the U.S.

BioMarin wins approval for gene therapy to treat hemophilia A

PBMs drew scrutiny in House hearing — and so did pharma

Information blocking fines are now fair game in health care

The cancer drug shortage isn’t new — and neither are the solutions

knowledge

focus

focus

leisure time